GU Cancers 2024 | Erdafitinib and enfortumab vedotin in pretreated FGFR2/3-mutant bladder cancer

Rohit Jain, MD, MPH, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, provides an overview of findings from a Phase Ib trial (NCT04963153), which assessed erdafitinib and enfortumab vedotin in patients with FGFR2/3-mutant metastatic urothelial carcinoma (mUC), who have progressed on platinum-based chemotherapy and/or PD-(L)1 inhibitors. Preliminary results show feasibility and early signs of antitumor activity and dose escalation is ongoing to elucidate the maximum tolerable dose. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.